Introducing RES4PRIOPATH: An Integrated Antiviral Discovery Platform of Broad-Spectrum Small Molecule Inhibitors of Viral Targets from Priority Preparedness Pathogens founded by ISIDORe´s Joint Research Activities Programme 2023-2025.
March 12, 2024
We are thrilled to announce the launch of RES4PRIOPATH, a groundbreaking consortium coordinated by MEDINA which aims to identify small molecule inhibitors for new emerging viruses flagged in genetic surveillances.
RESP4PRIOPATH is a collaborative effort that merges the capabilities of 4 European research infrastructures: EU-OPENSCREEN, INSTRUCT-ERIC, ERINHA and EATRIS, through a consortium comprised by the following partners: MEDINA-EU-OPENSCREEN-ES, CCMF-EUOPENSCREEN-DE, IBBMedChem-OPENSCREEN-PAN, GUF-BMRZ, CIRMMP-CERM-Instruct-IT , CERBM-IGBMC-Instruct-FR, UH-Instruct-FI, KULCapsIt-ERINHA-BE, and iMM-EATRIS-PT. This team of experts counts on complementary skills including high-throughput screening, drug discovery, protein expression, structural biology and virology.
ISIDORe´s founding has enabled the assembly of the consortium, which will focus on developing a European platform to quickly identify antivirals for potential pandemic viruses with no therapies available. These demonstrator cases will consolidate fast-tracking workflows and preparedness tools to respond to new variants of concern of known viruses or even to new ones.
